MedCity News
DECEMBER 19, 2024
AI should augment, not replace, human provider expertise. Explainability empowers healthcare professionals to work in tandem with AI, ensuring that patients receive the most accurate and informed care. The post Unlocking AI Explainability for Trustworthy Healthcare appeared first on MedCity News.
Fierce Pharma
DECEMBER 17, 2024
Johnson & Johnson has received coal in its stocking from the FDA as manufacturing issues have tripped up the companys attempt to gain approval of its subcutaneous version of lung cancer drug R | The FDA has sent complete response letters to Johnson & Johnson and AstraZeneca, rejecting J&J's application for subcutaneous Rybrevant and AZ's bid for a full approval of Andexxa.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 19, 2024
At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.
PM360
DECEMBER 20, 2024
Established in 2012, PM360 introduced the first-ever issue focused entirely on our industrys latest innovations. Categories explore every sector of the healthcare industry, from life sciences to marketing. PM360 would like to welcome you to the new age of innovation with our illuminating Innovations Issue. This yearly special issue has served as your go-to guide for the most interesting advancements in our industry over the past 13 years, by featuring a focussed view of 11 different areas in hea
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
DECEMBER 18, 2024
SiteOne Therapeutics develops drugs that target sodium channels, the wiring in the body that transmits pain signals. Because SiteOnes targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system. The post Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds appeared first on MedCity News.
Fierce Pharma
DECEMBER 17, 2024
Its not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisks diabetes superstar Ozempic and blindness? | After the recent release of two independent studies from the University of Southern Denmark suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the Danish Medicines Agency has asked European officials to investigate.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PM360
DECEMBER 20, 2024
In the high-stakes world of healthcare, the relationship between pharmaceutical advertising and the people it aims to reach is at a critical crossroads. For far too long, underserved communities have seen little in these ads that speak to their lives let alone their unique healthcare journeys. Now more than ever, the industry is recognizing that diversity, equity, and inclusion (DEI) are not just add-ons, but essential elements that define successful, meaningful campaigns.
MedCity News
DECEMBER 16, 2024
Now, more than ever, healthcare organizations must strive to innovate to ensure continuous patient care delivery while keeping medical staff safe. The post Healthcare Organizations Can, and Should, Provide Continuous Patient Carewith the Right Technology appeared first on MedCity News.
Fierce Pharma
DECEMBER 19, 2024
In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year. | Novartis confirmed Thursday that its closing down MorphoSys sites in Munich and Boston in a move thats expected to result in around 330 layoffs. The company made the decision in November as it looks to integrate all portfolio activities into Novartis.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
DECEMBER 20, 2024
Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.
MedCity News
DECEMBER 17, 2024
WellTheory has launched a new program that will address the link between autoimmune disease and hormone imbalances. The post WellTheory Announces Womens Health Program to Address Hormonal Conditions appeared first on MedCity News.
Fierce Pharma
DECEMBER 16, 2024
Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDAs checkpoint with its PD-L1 inhibitor cosibelimab. | Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDAs checkpoint with its PD-L1 inhibitor cosibelimab.
pharmaphorum
DECEMBER 19, 2024
Neuralink rival Precision Neurosciences raises $102m for its brain-computer interface tech, plus financings for Redesign, DeepLife, TG0 and Tuva.
Pharmaceutical Technology
DECEMBER 20, 2024
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.
MedCity News
DECEMBER 16, 2024
Neurocrine Biosciences Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million. The post Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder appeared first on MedCity News.
Fierce Pharma
DECEMBER 19, 2024
The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. | The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. The agencys move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound.
pharmaphorum
DECEMBER 18, 2024
SiteOne Therapeutics has completed a $100 million third-round financing that will support clinical trials of its non-opioid painkiller.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
DECEMBER 20, 2024
Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.
MedCity News
DECEMBER 18, 2024
Like any other tool, understanding the right problem to apply it to is the difference between success and failure. Addressing a problem is never just about technology; its always about people, processes, and technology. The post The AI Advantage: Reimagining the Future of Drug Development appeared first on MedCity News.
Fierce Pharma
DECEMBER 19, 2024
Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. | Following in the footsteps of Pfizer, Roche and Takeda, another ALK inhibitor has made its belated entry into the U.S. The FDA nod comes four years after its initial approval in China.
European Pharmaceutical Review
DECEMBER 20, 2024
Bristol Myers Squibb has licensed an amyloid-beta antibody programme from BioArctic AB. The PyroGlutamate-amyloid-beta (PyroGlu-A) programme includes novel antibodies (BAN1503 and BAN2803). These target a truncated, pyroglutamate modified form of amyloid-beta. BAN2803 utilises a technology platform that optimises biologic drug delivery past the blood brain barrier, BioArctic noted.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
DECEMBER 19, 2024
Ottimo raises $140m for PD-1 and VEGF-targeting jankistomig, which the startup says is differentiated from bispecific antibodies in the class.
MedCity News
DECEMBER 18, 2024
Discover the cutting-edge AI software that empowers trauma and critical care teams with real-time, data-driven insights. The post TraumaCare.AI shaping the future of critical care with AI-powered innovation appeared first on MedCity News.
Fierce Pharma
DECEMBER 17, 2024
Its the end of an era at Jazz Pharmaceuticals as the drugmakers co-founder and CEO, Bruce Cozadd, eyes his exit after nearly 22 years with the companysome 15 of which were spent at the helm. | Current helmsman Bruce Cozadd plans to retire from his role at Jazz Pharmaceuticals in the next 12 months, the company said Monday. Jazz aims to complete its search for a CEO successor by the end of 2025, after which Cozadd will stay on board as the drugmaker's board chair.
Pharmaceutical Technology
DECEMBER 18, 2024
Abera and Orexo have entered a partnership to develop and test the powder formulations of the formers vaccine candidates.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmaVoice
DECEMBER 20, 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
MedCity News
DECEMBER 15, 2024
How top-to-bottom collaboration can alleviate hurdles and help increase equitable access to the most effective treatments for all cancer patients. The post Closing the Gap: Advancing Precision Oncology Through Education and Collaboration appeared first on MedCity News.
Fierce Pharma
DECEMBER 17, 2024
After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.< | After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.
Pharmaceutical Technology
DECEMBER 20, 2024
The US FDA has approved Ionis' TRYNGOLZA (olezarsen) as an adjunct to diet for reducing triglyceride levels in the adult population with FCS
Expert insights. Personalized for you.
102 
Let's personalize your content